Table
2: Baseline
characteristics of the three treatment regimen groups.
|
|
Daclatasvir with Asunaprevir |
Sofosbuvir with Ledipasvir |
Sofosbuvir plus Ribavirin |
|
Mean age, year |
68.4 ± 7.6 |
71.0 ± 74.4 |
67.4 ± 9.2 |
|
Sex, female/male |
52/36 |
6/8 |
7/4 |
|
BMI, kg/m2 |
23.4 ± 3.6 |
23.1 ± 3.3 |
23.6 ± 3.6 |
|
White blood cellｓ, 103/dL |
3.81 ± 1.38 |
3.94 ± 1.27 |
3.86 ± 1.32 |
|
Hemoglobin, g/dL |
12.8 ± 1.6 |
12.3 ± 1.8 |
12.9 ± 1.4 |
|
Platelets, 104/μL |
7.6 ± 1.8 |
7.1 ± 1.8 |
8.0 ± 1.6 |
|
AST, IU/L |
86.0 ± 49.0 |
49.0 ± 15.5 |
103.4 ± 78.0 |
|
ALT, IU/L |
76.9 ± 47.1 |
44.1 ± 21.0 |
73.8 ± 36.5 |
|
eGFR,
mL/min |
70.2 ± 14.2 |
70.8 ± 12.7 |
66.4 ± 18.6 |
|
CTP score, no. (%) |
|||
|
5 |
48 (54.5%) |
7 (50%) |
5 (45.5%) |
|
6 |
20 (22.7%) |
3 (21.4%) |
4 (36.4%) |
|
7 |
10 (11.3%) |
2 (14.3%) |
1 (9.1%) |
|
8 |
10 (11.3%) |
2 (14.3%) |
1 (9.1%) |
|
MELD score, no. (%) |
|||
|
< 10 |
79 (89.8%) |
13 (92.9%) |
9 (81.8%) |
|
10-15 |
8 (9.1%) |
1 (7.1%) |
2 (18.2%) |
|
≥ 15 |
1 (1.1%) |
0 |
0 |
|
Ascites, no. (%) |
|||
|
None |
79 (89.8%) |
13 (92.9%) |
10 (90.9%) |
|
Mild |
4(4.5%) |
1 (7.1%) |
1 (9.1%) |
|
Moderate |
3 (3.4%) |
0 |
0 |
|
Severe |
2 (2.3%) |
0 |
0 |
|
CSPH, no. (%) |
19 (26.1%) |
4 (28.6%) |
3 (27.2%) |
|
Hepatocellular Carcinoma, no. (%) |
|||
|
None |
56 (63.6%) |
8 (57.1%) |
8 (72.7%) |
|
Post Treatment |
32 (36.4%) |
6 (42.9%) |
3 (27.3%) |
|
HCV genotype |
1b |
1b |
2 |
|
HCV RNA, Log10 IU/mL |
6.0 ± 0.8 |
5.5 ± 1.0 |
5.7 ± 0.7 |
|
Previous HCV Treatment, no. |
|||
|
No |
50 |
10 |
5 |
|
Yes |
38 |
4 |
6 |
|
TVR or SMV triple therapy |
10 |
1 |
0 |
|
PEG-IFN plus RBV |
28 |
4 |
6 |
|
SVR12, % (n/n) |
92.0% (81/88) |
100% (14/14) |
100% (11/11) |
|
Serious AE, no. (%) |
2 (2.3%) |
0 |
0 |
PEG-IFN:
Pegylated Interferon; RBV: Ribavirin; SMV: Simeprevir; TVR: Telaprevir